HIV-derived vectors for therapy and vaccination against HIV - PubMed (original) (raw)
Review
. 2012 Mar 28;30(15):2499-509.
doi: 10.1016/j.vaccine.2012.01.089. Epub 2012 Feb 13.
Affiliations
- PMID: 22342915
- DOI: 10.1016/j.vaccine.2012.01.089
Review
HIV-derived vectors for therapy and vaccination against HIV
F Di Nunzio et al. Vaccine. 2012.
Abstract
Despite being at the origin of one of the world's most devastating public health concerns, the Human Immunodeficiency Virus (HIV) has properties that can be harnessed for therapeutic purposes. Indeed, the ability of HIV to efficiently deliver its genome into the nuclear compartment makes it an ideal vector for gene delivery into target cells. The design of so-called HIV-derived vectors, or more generally lentiviral vectors (LVs), consists in keeping only the parts of the virus that ensure efficient nuclear delivery while entirely removing all coding sequences that contribute towards the replication and pathogenesis of the virus: as a result, the vector genome is composed of less than 10% of the original virus genome and exclusively cis-active sequences. Proteins required for the formation of the lentivector particles and for the early steps of viral replication (including Gag- and Pol-derived proteins) are provided in trans. HIV-derived vectors are thus non-replicative virus shells that deliver genes of interest into target cells with high efficiency. Undoubtedly, there is a hopeful twist of fate in our fight against AIDS, which consists in using these vectors to achieve gene therapy and vaccination against HIV itself. This review summarises the current generation of LVs with a special focus on vaccine applications against AIDS. Preclinical data are very encouraging and efforts are ongoing to optimise these vectors, to increase their safety and improve their immunogenicity.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
- Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.
Chang LJ, Liu X, He J. Chang LJ, et al. Gene Ther. 2005 Jul;12(14):1133-44. doi: 10.1038/sj.gt.3302509. Gene Ther. 2005. PMID: 15750613 - Development of a novel trans-lentiviral vector that affords predictable safety.
Wu X, Wakefield JK, Liu H, Xiao H, Kralovics R, Prchal JT, Kappes JC. Wu X, et al. Mol Ther. 2000 Jul;2(1):47-55. doi: 10.1006/mthe.2000.0095. Mol Ther. 2000. PMID: 10899827 - Lentiviral vectors for HIV disease prevention and treatment.
Lemiale F, Korokhov N. Lemiale F, et al. Vaccine. 2009 May 26;27(25-26):3443-9. doi: 10.1016/j.vaccine.2009.01.055. Epub 2009 Feb 6. Vaccine. 2009. PMID: 19201386 Review. - Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, Rosenblatt J. Klimatcheva E, et al. Mol Ther. 2001 Jun;3(6):928-39. doi: 10.1006/mthe.2001.0344. Mol Ther. 2001. PMID: 11407907 - Retroviral vectors for gene therapy of AIDS and cancer.
Chang LJ, He J. Chang LJ, et al. Curr Opin Mol Ther. 2001 Oct;3(5):468-75. Curr Opin Mol Ther. 2001. PMID: 11699891 Review.
Cited by
- Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Ku MW, Bourgine M, Authié P, Lopez J, Nemirov K, Moncoq F, Noirat A, Vesin B, Nevo F, Blanc C, Souque P, Tabbal H, Simon E, Hardy D, Le Dudal M, Guinet F, Fiette L, Mouquet H, Anna F, Martin A, Escriou N, Majlessi L, Charneau P. Ku MW, et al. Cell Host Microbe. 2021 Feb 10;29(2):236-249.e6. doi: 10.1016/j.chom.2020.12.010. Epub 2020 Dec 16. Cell Host Microbe. 2021. PMID: 33357418 Free PMC article. - Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses.
Dérian N, Bellier B, Pham HP, Tsitoura E, Kazazi D, Huret C, Mavromara P, Klatzmann D, Six A. Dérian N, et al. PLoS Comput Biol. 2016 Mar 21;12(3):e1004801. doi: 10.1371/journal.pcbi.1004801. eCollection 2016 Mar. PLoS Comput Biol. 2016. PMID: 26998760 Free PMC article. - Long-term central and effector SHIV-specific memory T cell responses elicited after a single immunization with a novel lentivector DNA vaccine.
Arrode-Brusés G, Moussa M, Baccard-Longere M, Villinger F, Chebloune Y. Arrode-Brusés G, et al. PLoS One. 2014 Oct 22;9(10):e110883. doi: 10.1371/journal.pone.0110883. eCollection 2014. PLoS One. 2014. PMID: 25337803 Free PMC article. - A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs.
de Wispelaere M, Ricklin M, Souque P, Frenkiel MP, Paulous S, Garcìa-Nicolàs O, Summerfield A, Charneau P, Desprès P. de Wispelaere M, et al. PLoS Negl Trop Dis. 2015 Oct 5;9(10):e0004081. doi: 10.1371/journal.pntd.0004081. eCollection 2015. PLoS Negl Trop Dis. 2015. PMID: 26437302 Free PMC article. - Corrigendum: Recent Advances in Lentiviral Vaccines for HIV-1 Infection.
Norton TD, Miller EA. Norton TD, et al. Front Immunol. 2016 Sep 14;7:354. doi: 10.3389/fimmu.2016.00354. eCollection 2016. Front Immunol. 2016. PMID: 27630642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical